Williams E F, Barker P H, Clanachan A S
Can J Physiol Pharmacol. 1984 Jan;62(1):31-7. doi: 10.1139/y84-005.
The site-specific binding of the potent and selective nucleoside transport inhibitor, [3H]nitrobenzylthioinosine (NBMPR), to the nucleoside transport system of cardiac membranes of several species was investigated. The affinity of [3H]NBMPR for these sites ranged from 0.03 nM in rat to 0.78 nM in dog. The maximal binding capacity of cardiac membranes for [3H]NBMPR was also species dependent and was greatest in bovine and guinea pig heart (2551 and 1700 fmol/mg protein, respectively) and least in rat (195 fmol/mg protein). The affinities of recognized nucleoside transport inhibitors and benzodiazepines for these transport inhibitory sites in guinea pig and rat heart were estimated by studying the inhibition of the site-specific binding of [3H]NBMPR in competition experiments. These values were compared with their inhibitory effects on the transporter-dependent accumulation of [3H]adenosine in guinea pig and rat cardiac muscle segments and with their ability to potentiate the negative inotropic action of adenosine in electrically driven guinea pig and rat left atria. In guinea pig heart, the recognized nucleoside transport inhibitors and benzodiazepines had an order of affinity (dilazep greater than hydroxynitrobenzylthioguanosine greater than dipyridamole greater than hexobendine much greater than lidoflazine much greater than flunitrazepam greater than diazepam greater than lorazepam greater than flurazepam) for the NBMPR site which was similar to those for the inhibition of [3H]adenosine accumulation and for potentiation of adenosine action. In contrast, in rat heart, where the maximal binding capacity of [3H]NBMPR was lower (eightfold), the nucleoside transporter dependent accumulation of [3H]adenosine was also lower (sixfold) and the negative inotropic action of adenosine was not significantly potentiated.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了强效选择性核苷转运抑制剂[3H]硝基苄硫基肌苷(NBMPR)与几种动物心脏膜核苷转运系统的位点特异性结合。[3H]NBMPR对这些位点的亲和力范围为:大鼠为0.03 nM,犬为0.78 nM。心脏膜对[3H]NBMPR的最大结合容量也因物种而异,在牛和豚鼠心脏中最大(分别为2551和1700 fmol/mg蛋白质),在大鼠中最小(195 fmol/mg蛋白质)。通过在竞争实验中研究[3H]NBMPR位点特异性结合的抑制作用,估算了豚鼠和大鼠心脏中公认的核苷转运抑制剂和苯二氮䓬类药物对这些转运抑制位点的亲和力。将这些值与其对豚鼠和大鼠心肌段中[3H]腺苷转运体依赖性积累的抑制作用以及它们增强腺苷对电驱动的豚鼠和大鼠左心房负性肌力作用的能力进行了比较。在豚鼠心脏中,公认的核苷转运抑制剂和苯二氮䓬类药物对NBMPR位点的亲和力顺序(双嘧达莫大于羟基硝基苄硫基鸟苷大于双嘧达莫大于己酮可可碱远大于利多氟嗪远大于氟硝西泮大于地西泮大于劳拉西泮大于氟西泮)与抑制[3H]腺苷积累和增强腺苷作用的顺序相似。相比之下,在大鼠心脏中,[3H]NBMPR的最大结合容量较低(八倍),[3H]腺苷的核苷转运体依赖性积累也较低(六倍),腺苷的负性肌力作用没有明显增强。(摘要截短于250字)